[1]

陈灏珠, 林果为. 实用内科学. 13版. 北京: 人民卫生出版社, 2009.
[2] Delbeke D, Martin WM.  PET and PET/CT for pancreatic malignanies[J]. Surg Oncol Clin N Am, 2010, 19(2): 235-254.   doi: 10.1016/j.soc.2009.11.005
[3] Dewitt J, Devereaux BM, Lehman GA, et al.  Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review[J]. Clin Gastroenterol Hepatol, 2006, 4(6): 717-725.   doi: 10.1016/j.cgh.2006.02.020
[4] Mertz HR, Sechopoulos P, Delbeke D, et al.  EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma[J]. Gastrointest Endosc, 2000, 52(3): 367-371.   doi: 10.1067/mge.2000.107727
[5] Vargas R, Nino-Murcia M, Trueblood W, et al.  MDCT in pancreatic adenocarcinoma: prediction of vascular invasion and resectability using a multiphasic technique with curved planar reformations[J]. AJR Am J Roentgenol, 2004, 182(2): 419-425.   doi: 10.2214/ajr.182.2.1820419
[6] Park SS, Lee KT, Lee KH, et al.  Diagnostic usefulness of PET/CT for pancreatic malignancy[J]. Korean J Gastroenterol, 2009, 54(4): 235-242.   doi: 10.4166/kjg.2009.54.4.235
[7] Lemke AJ, Niehues SM, Hosten N, et al.  Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions—a prospective study with 104 patients[J]. J Nucl Med, 2004, 45(8): 1279-1286.
[8] Sperti C, Pasquali C, Decet G, et al.  F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study[J]. J Gastrointest Surg, 2005, 9(1): 22-28.   doi: 10.1016/j.gassur.2004.10.002
[9] Sperti C, Bissoli S, Pasquali C, et al.  18-Fluorodeoxy glucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas[J]. Ann Surg, 2007, 246(6): 932-937.   doi: 10.1097/SLA.0b013e31815c2a29
[10] Nishiyama Y, Yamamoto Y, Yokoe K, et al.  Contribution of whole body FDG PET to the detection of distant metastasis in pancreatic cancer[J]. Ann Nucl Med, 2005, 19(6): 491-497.   doi: 10.1007/BF02985577
[11]

Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods(US, CT, MR imaging, PET): a meta-analysis. 2002, 224(3): 748-756.
[12] Farma JM, Santillan AA.  PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms[J]. Ann Surg Oncol, 2008, 15(9): 2465-2471.   doi: 10.1245/s10434-008-9992-0
[13] Kysucan J, Lovecek M, Klos D, et al.  Benefit of PET/CT in the preoperative staging in pancreatic carcinomas[J]. Rozhl Chir, 2010, 89(7): 433-440.
[14] Saif MW, Cornfeld D, Modarresifar H, et al.  18F-FDG positron emission tomography CT(FDG PET-CT)in the management of pancreatic cancer: Initial experience in 12 patients[J]. J Gastrointestin Liver Dis, 2008, 17(2): 173-178.
[15] Topkan E, Yavuz AA, Avdin M, et al.  Comparison of CT and PETCT based planning of radiation therapy in locally advanced pancreatic carcinoma[J]. J Exp Clin Cancer Res, 2008, 27(1): 41-.   doi: 10.1186/1756-9966-27-41
[16] Therasse P, Arbuck SG, Eisenhauer EA, et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J]. J Natl Cancer Inst, 2000, 92(3): 205-216.   doi: 10.1093/jnci/92.3.205
[17] Heinrich S, Schäfer M, Weber A, et al.  Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial[J]. Ann Surg, 2008, 248(6): 1014-1022.   doi: 10.1097/SLA.0b013e318190a6da
[18] Choi M, Heilbrun LK, Venkatramanamoorthy R, et al.  Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer[J]. Am J Clin Oncol, 2010, 33(3): 257-261.   doi: 10.1097/COC.0b013e3181a76a0b
[19] Schellenberg D, Quon A, Minn AY, et al.  18 Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2010, 77(5): 1420-1425.   doi: 10.1016/j.ijrobp.2009.06.049
[20] Lee TY, Kim MH.  Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer[J]. AJR Am J Roentgenol, 2009, 193(2): 343-348.   doi: 10.2214/AJR.08.2297
[21] 王欣, 于丽娟.  18F-FDG PET/CT综合分析法在胰腺癌诊断中的价值[J]. 中国医学影像技术, 2007, 23(11): 1709-1712.   doi: 10.3321/j.issn:1003-3289.2007.11.036
[22] Zimny M, Bares R, Fass J, et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases[J]. EurJ Nucl Med, 1997, 24(6): 678-682.
[23] Samnick S, Romeike BF, Kubuschok B, et al.  p-[123I]iodo-L-phenylalanine for detection of pancreatic cancer: basic investigations of the uptake characteristics in primary human pancreatic tumour cells and evaluation in in vivo models of human pancreatic adenocarcinoma[J]. EurJ Nucl Med Mol Imaging, 2004, 31(4): 532-541.   doi: 10.1007/s00259-003-1445-1
[24] Flores LG, Bertolini S, Yeh HH, et al.  Detection of pancreatic carcinomas by imaging lactose-binding protein expression in peritumoral pancreas using[18F]fluoroethyl-deoxy lactose PE T/CT[J]. PLoS ONE, 2009, 4(11): e7977-.   doi: 10.1371/journal.pone.0007977